The Clinical Outcomes and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and HR+/HER2-Breast Cancer: A Multicenter Observational Study from Turkey

Tarih

Yazarlar

Yucel, Mehmet Haluk

Celayir, Ozde Melisa

Uluc, Basak Oyan

Selcukbiricik, Fatih

DOI No

10.3390/cancers17091592

Diğer Tanımlayıcı No

WOS:001486131800001

Yayınevi

Anahtar kelimeler

sacituzumab govitecan, real\\-world data, metastatic breast cancer, triple\\-negative breast cancer, hormone receptor\\-positive breast cancer, Trop\\-2, antibody\\-drug conjugate

URI

https://openaccess.acibadem.edu.tr/handle/11443/5021

Koleksiyonlar

Tam öğe sayfası